• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

LifeMD Integrates with Withings: GLP-1 Weight Loss with In-Home Monitoring

by Syed Hamza Sohail 05/02/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

 What You Should Know:

–              LifeMD, Inc.® (Nasdaq: LFMD), a leading provider of virtual primary care services, and Withings Health Solutions, a leader in digital health technology, announce a new strategic partnership designed to revolutionize weight management patient care by providing LifeMD’s GLP-1 weight-loss patients with Withings advanced in-home health monitoring devices, including the Body Pro 2 scale and the BPM Connect Pro blood pressure monitor.

–              With these devices, LifeMD is setting a new standard in virtual care by providing clinicians with near real-time and actionable patient data that can drive compliance, enhance clinical decision-making, encourage preventive healthcare, and, most importantly, improve long-term outcomes.

Revolutionizing Weight Loss Treatment: The Integration of Digital Health Technology and GLP-1 Therapy by LifeMD and Withings

LifeMD’s GLP-1 weight-loss program stands out as a unique support system for patients embarking on their weight-loss journey. It facilitates accessible healthy living through online consultations with licensed clinicians, prescriptions for weight management medications, and orders for full-service laboratory testing. Leveraging detailed health data from Withings’ in-home health monitoring devices, LifeMD aims to gain deeper insights into the effectiveness of GLP-1 treatments and their impact on overall health. This partnership also sets the stage for pioneering real-world evidence studies.

The Body Pro 2, the inaugural cellular body composition scale, not only measures weight but also offers a comprehensive analysis of body composition, encompassing body fat, muscle mass, water percentage, and bone mass. Equipped with features like Personalized Health Nudges and ProgramMemberID, exclusive to Withings, the device places patient care at the forefront. Personalized messages can be sent to patients via the scale’s screen, ensuring that measurements are attributed to the correct patient.

BPM Connect Pro provides medically accurate blood pressure monitoring, allowing healthcare providers to monitor changes in blood pressure alongside weight-loss progress. As GLP-1 medications can reduce the risk of cardiovascular events, BPM Connect Pro provides LifeMD-affiliated providers with a holistic view of their patients’ progress and the ability to adjust medications as needed.

Both devices employ cellular connectivity, ensuring that LifeMD receives continuous, HIPAA-compliant, accurate, and reliable measurements. These measurements are displayed in near real-time via the LifeMD patient portal, accessible to both patients and clinical teams. Thanks to cellular connectivity, the devices are ready to use out of the box and require no installation.

This partnership represents a significant advancement in GLP-1 weight-loss treatment and showcases the potential of digital health technology to revolutionize patient care and outcomes in the virtual care landscape.

LifeMD, a premier provider of virtual primary care, offers telemedicine, laboratory and pharmacy services, and specialized treatment for over 200 conditions. These services encompass primary care, men’s and women’s health, weight management, and hormone therapy.

“By being one of the first to monitor body composition in GLP-1 weight-loss programs, LifeMD is pioneering a comprehensive approach to weight management. This collaboration underscores our shared commitment not just to weight management but to a deeper understanding of a patient’s health,” said Antoine Robiliard, VP of Withings Health Solutions. “LifeMD’s dedication to leveraging advanced technology to enhance the patient experience aligns perfectly with our vision. Our cellular devices, with patient engagement features, will help LifeMD’s teams drive consistent patient engagement and benefit from larger datasets to make more informed decisions.”

 What You Should Know:

–              LifeMD, Inc.® (Nasdaq: LFMD), a leading provider of virtual primary care services, and Withings Health Solutions, a leader in digital health technology, announce a new strategic partnership designed to revolutionize weight management patient care by providing LifeMD’s GLP-1 weight-loss patients with Withings advanced in-home health monitoring devices, including the Body Pro 2 scale and the BPM Connect Pro blood pressure monitor.

–              With these devices, LifeMD is setting a new standard in virtual care by providing clinicians with near real-time and actionable patient data that can drive compliance, enhance clinical decision-making, encourage preventive healthcare, and, most importantly, improve long-term outcomes.

Revolutionizing Weight Loss Treatment: The Integration of Digital Health Technology and GLP-1 Therapy by LifeMD and Withings

LifeMD’s GLP-1 weight-loss program stands out as a unique support system for patients embarking on their weight-loss journey. It facilitates accessible healthy living through online consultations with licensed clinicians, prescriptions for weight management medications, and orders for full-service laboratory testing. Leveraging detailed health data from Withings’ in-home health monitoring devices, LifeMD aims to gain deeper insights into the effectiveness of GLP-1 treatments and their impact on overall health. This partnership also sets the stage for pioneering real-world evidence studies.

The Body Pro 2, the inaugural cellular body composition scale, not only measures weight but also offers a comprehensive analysis of body composition, encompassing body fat, muscle mass, water percentage, and bone mass. Equipped with features like Personalized Health Nudges and ProgramMemberID, exclusive to Withings, the device places patient care at the forefront. Personalized messages can be sent to patients via the scale’s screen, ensuring that measurements are attributed to the correct patient.

BPM Connect Pro provides medically accurate blood pressure monitoring, allowing healthcare providers to monitor changes in blood pressure alongside weight-loss progress. As GLP-1 medications can reduce the risk of cardiovascular events, BPM Connect Pro provides LifeMD-affiliated providers with a holistic view of their patients’ progress and the ability to adjust medications as needed.

Both devices employ cellular connectivity, ensuring that LifeMD receives continuous, HIPAA-compliant, accurate, and reliable measurements. These measurements are displayed in near real-time via the LifeMD patient portal, accessible to both patients and clinical teams. Thanks to cellular connectivity, the devices are ready to use out of the box and require no installation.

This partnership represents a significant advancement in GLP-1 weight-loss treatment and showcases the potential of digital health technology to revolutionize patient care and outcomes in the virtual care landscape.

LifeMD, a premier provider of virtual primary care, offers telemedicine, laboratory and pharmacy services, and specialized treatment for over 200 conditions. These services encompass primary care, men’s and women’s health, weight management, and hormone therapy.

“By being one of the first to monitor body composition in GLP-1 weight-loss programs, LifeMD is pioneering a comprehensive approach to weight management. This collaboration underscores our shared commitment not just to weight management but to a deeper understanding of a patient’s health,” said Antoine Robiliard, VP of Withings Health Solutions. “LifeMD’s dedication to leveraging advanced technology to enhance the patient experience aligns perfectly with our vision. Our cellular devices, with patient engagement features, will help LifeMD’s teams drive consistent patient engagement and benefit from larger datasets to make more informed decisions.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: GLP-1

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |